Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys.
An analogue of primaquine, N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl) 1,4-pentanediamine, CDRI Code 80/53), has been evaluated for anti-relapse activity against sporozoite induced Plasmodium cynomolgi B infection in rhesus monkeys. The compound has shown 100% curative anti-relapse activity at 1.25 mg/kg x 7 day dose schedule, thereby giving a primaquine index of 0.8. The compound is currently under Phase-I clinical trials.
Dutta
G P
GP
Division of Microbiology and Medicinal Chemistry, Central Drug Research Institute, Lucknow, India.
Puri
S K
SK
Bhaduri
A P
AP
Seth
M
M
D000634:Aminoquinolines / Q000627:therapeutic use*; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D008253:Macaca mulatta; D008288:Malaria / Q000188:drug therapy*; D015394:Molecular Structure; D011319:Primaquine / Q000627:therapeutic use / Q000031:analogs & derivatives
D000634:Aminoquinolines; D000962:Antimalarials; D011319:Primaquine; C063469:bulaquine